DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Dan Brennan - 5 Cowen - 3 Francis deSouza - 2 Carl Icahn - 2 Icahn - 2 Illumina - 2 Charles Dadswell - 2 DeSouza - 2
Top related locs:
Occidental Bengaluru New York New Jersey Stifel Needham Illumina London
Top related orgs:
Nasdaq - 3 LinkedIn - 2 Unilever Plc - 2 U.S . Federal Trade Commission - 2 Thomson - 2 Bank of America - 1 Tempus - 1 America's - 1

Search resuls for: "Dan Brennan"


7 mentions found


☆ TD Cowen's Dan Brennan on why he's bullish on Tempus
  + stars: | 2024-07-09 | by ( ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailTD Cowen's Dan Brennan on why he's bullish on TempusDan Brennan, senior analyst at TD Cowen, joins CNBC's 'The Exchange' to discuss his price target on Tempus, AI in diagnostics, and more.
Persons: Dan Brennan, Cowen
☆ Wall Street analysts love this recent IPO that's an AI play in the health-care sector
  + stars: | 2024-07-09 | by ( Lisa Kailai Han | ) www.cnbc.com   time to read: +2 min
Wall Street analysts are bullish on recently launched health-care technology stock Tempus AI . By combining a patient's molecular, clinical, and imaging data with its AI platform, Tempus delivers personalized therapy decisions," he wrote. Tempus AI debuted at the Nasdaq on June 14, closing at $40 after pricing its initial public offering at $37. Last month, investment management firm SoftBank announced it had invested about $200 million in Tempus AI before its Nasdaq listing. Since its debut, Tempus AI stock has slipped 10% from its IPO price.
Persons: Michael Ryskin, SoftBank, America's Ryskin, Ryskin, JPMorgan's Rachel Vatnsdal, William Blair, Morgan Stanley, Tejas Savant, TD Cowen, Dan Brennan Organizations: Bank of America, Tempus, Nasdaq, America's, Precision Oncology, Loop Capital Locations: Stifel, Needham
☆ Illumina CEO deSouza resigns after proxy battle with Icahn
  + stars: | 2023-06-12 | by ( ) www.reuters.com   time to read: +3 min
The Grail deal "has kept a lot of investors out of the stock" TD Cowen analyst Dan Brennan said. The company's shares have lost about 60% of their value since completing the Grail deal in 2021. Illumina shares closed at $200.53 on the Nasdaq on Friday. Icahn has said he wants former Illumina CEO Jay Flatley to return. He had secured more than twice the number of shareholder votes than his challenger received in the proxy vote, which could have given him enough legitimacy to hang on.
Persons: Francis deSouza, Carl Icahn, Icahn, Illumina, Charles Dadswell, DeSouza, deSouza's, Cowen, Dan Brennan, Francis, John Thompson, Andrew Teno, Jay Flatley, Vicki Hollub, Alan Jope, Management's Nelson Peltz, Lavanya, Caroline Humer, Michael Erman, Anirban Sen, Mark Porter, Marguerita Choy, Edwina Gibbs Organizations: Nasdaq, LinkedIn, Unilever Plc, U.S . Federal Trade Commission, Thomson Locations: Illumina, Occidental, Bengaluru, New York, New Jersey
☆ Illumina CEO deSouza resigns after battle with Icahn
  + stars: | 2023-06-11 | by ( ) www.reuters.com   time to read: +3 min
Analysts said they expect the company's shares to trade up on Monday morning after deSouza's resignation. The Grail deal "has kept a lot of investors out of the stock" TD Cowen analyst Dan Brennan said. The company's shares have lost about 60% of their value since completing the Grail deal in 2021. Illumina shares closed at $200.53 on the Nasdaq on Friday. Icahn has said he wants former Illumina CEO Jay Flatley to return.
Persons: Francis deSouza, Carl Icahn, Illumina, Charles Dadswell, DeSouza, Icahn, deSouza's, Cowen, Dan Brennan, Francis, John Thompson, Andrew Teno, Jay Flatley, Vicki Hollub, Alan Jope, Management's Nelson Peltz, Lavanya, Caroline Humer, Michael Erman, Anirban Sen, Jason Neely, Jan Harvey, Mark Porter, Marguerita Choy Organizations: Nasdaq, LinkedIn, Unilever Plc, U.S . Federal Trade Commission, Thomson Locations: Occidental, Bengaluru, New York, New Jersey
☆ Billionaire Tom Siebel faces tumult at C3.ai as investor lawsuit, short sellers question metrics
  + stars: | 2023-06-02 | by ( Yasmin Khorram Paige Tortorelli | Yasmin Khorram | Paige Tortorelli | ) www.cnbc.com   time to read: +21 min
In their joint venture agreement, Baker Hughes says it uses C3.ai's solutions and also sells the product to companies in the oil and gas industry. CNBC's "Last Call" aired a report Thursday night on the investor lawsuit against C3.ai and the company's relationship with Baker Hughes. The lawsuit says the publicity about the massive Baker Hughes sales force "artificially inflated C3's stock" when the company first went public. Richard Drew | APIn an April 2023 filing, Baker Hughes announced it divested 1.7 million C3.ai shares, bringing its ownership to 6.9 million shares. Kerrisdale pointed to C3.ai's "highly conspicuous growth" in unbilled receivables, largely from Baker Hughes, and wrote that "accounting red flags abound with the Baker Hughes relationship."
Persons: Tom Siebel, Siebel, Thomas M, Chris J, Ratcliffe, it's, Baker Hughes, Logan Roy, Larry Ellison, Yasmin Khorram, Dan Brennan, We've, Brennan, he's, CNBC's, Reed Kathrein, Theranos, —, Kathrein, Richard Drew, they'd, unbilled, receivables, Siebel's, Ken Goldman, Goldman, Gil Luria, Davidson, Luria, Nick Wells, Scott Zamost, Sam Woodward, Tom Siebel's Organizations: Siebel Systems, Oracle, Bloomberg Tech Summit, Bloomberg, Getty, CNBC, Forbes, Siebel, C3, U.S . Department of Defense, Shell, Northern District of, SEC, Twitter, " Traders, New York Stock Exchange, AP, Point Capital Management, Spotify, C3 Energy, Revenue, Wall Locations: London, Redwood City , CA, Redwood City , California, Northern District, Northern District of California, unbilled receivables, Point
☆ This biotech can gain 50% thanks to interest in long-read sequencing technology, TD Cowen says
  + stars: | 2023-03-31 | by ( Sarah Min | ) www.cnbc.com   time to read: +2 min
It's time to take another look at Pacific Biosciences of California as its growth story turns positive, according to TD Cowen. "Our bullish customer survey reflects upside to placements and pull through, along with a material budget shift to long reads. Pacific Biosciences shares are up more than 19% this year through Thursday, gaining after a rough couple of calendar years. However, Brennan's $15 price target, up from a prior $13, means shares can rise another 53% from Thursday's closing price. Central to the upgrade is the Revio system, a product from Pacific Biosciences that was launched last year and is designed to sequence whole human genomes.
☆ Illumina Makes Its Interim CFO Permanent
  + stars: | 2023-02-01 | by ( Kristin Broughton | ) www.wsj.com   time to read: +3 min
Gene-sequencing company Illumina Inc. on Wednesday named Joydeep Goswami as chief financial officer, giving its interim CFO the role on a permanent basis. Mr. Goswami joined Illumina in 2019 as chief strategy and corporate development officer, overseeing strategic partnerships and acquisitions. Illumina CFO Joydeep Goswami. He added that he received a crash course in traditional areas of finance, including treasury, tax and audit, while serving as interim CFO. As CFO, Mr. Goswami plans to keep Illumina’s spending on innovation roughly constant as a percentage of revenue.
0 next >>
Total: 7